Shield Therapeutics Plc Stock Cash Flow From Operations
| SHIEF Stock | USD 0.1 0.00 0.00% |
Fundamental analysis of Shield Therapeutics allows traders to better anticipate movements in Shield Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Shield |
Shield Therapeutics plc OTC Stock Cash Flow From Operations Analysis
Shield Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Shield Therapeutics Cash Flow From Operations | (16.74 M) |
Most of Shield Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shield Therapeutics plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Shield Therapeutics plc has (16.74 Million) in Cash Flow From Operations. This is 103.17% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The cash flow from operations for all United States stocks is 101.72% higher than that of the company.
Shield Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shield Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Shield Therapeutics could also be used in its relative valuation, which is a method of valuing Shield Therapeutics by comparing valuation metrics of similar companies.Shield Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Shield Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | -0.34 | |||
| Operating Margin | (7.83) % | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 585.67 M | |||
| Shares Owned By Insiders | 42.23 % | |||
| Shares Owned By Institutions | 13.58 % | |||
| Price To Book | 0.75 X | |||
| Price To Sales | 7.37 X | |||
| Revenue | 1.52 M | |||
| Gross Profit | 539 K | |||
| EBITDA | (17.35 M) | |||
| Net Income | (19.34 M) | |||
| Cash And Equivalents | 2.4 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 156 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 2.60 X | |||
| Book Value Per Share | 0.15 X | |||
| Cash Flow From Operations | (16.74 M) | |||
| Earnings Per Share | (0.11) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.1 | |||
| Market Capitalization | 51.48 M | |||
| Total Asset | 44.41 M | |||
| Net Asset | 44.41 M |
About Shield Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shield Therapeutics plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shield Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shield Therapeutics plc based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Shield OTC Stock
Shield Therapeutics financial ratios help investors to determine whether Shield OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shield with respect to the benefits of owning Shield Therapeutics security.